Common Stock and Common Stock Equivalents (Narrative) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Apr. 07, 2023	Dec. 10, 2020	Dec. 03, 2018
Common Stock And Common Stock Equivalents [Line Items]
Common share sold,value	$ 34,355,315	$ 33,533,003
Equity incentive paln,description	On December 3, 2018, the shareholders approved the 2018 equity incentive plan ("2018 Equity Plan"), setting aside 120,000 shares of common stock. On December 10, 2020, the shareholders approved a new 2020 equity incentive plan ("2020 Equity Plan"), setting aside 200,000 shares of common stock. Shares remaining available under the 2018 Equity Plan are eligible for use under the 2020 Equity Plan. Incentive and nonqualified stock options, restricted common stock, stock appreciation rights, and other share-based awards may be granted under the plans including performance-based awards.
Share authorised and reseved for issuance	198,084			200,000	120,000
Stock-based compensation expense	$ 131,336	178,148
Unrecognized stock-based compensation cost	$ 41,808
Years over which unrecognized stock-based compensation expense is expected to be recognized	2 years
Aggregate intrinsic value of options outstanding	$ 0	$ 0
Canaccord Geneuity LLC And Roth Capital Partners LLC [Member]
Common Stock And Common Stock Equivalents [Line Items]
Common share sold,value	3,875,150		$ 2,671,513
Aggregate market value of securities	$ 75,000,000
Commision rate on gross sale price per share	3.00%
Director [Member]
Common Stock And Common Stock Equivalents [Line Items]
Restricted common share granted	10,000	12,000
Employee [Member]
Common Stock And Common Stock Equivalents [Line Items]
Restricted common share granted	26,048	12,001